MAPT and Alzheimer disease: To this aim, we examined and compared, in the eyes of 6-month-old animals from three experimental groups (littermate wild-type, naive/vehicle-treated Tg-AD, Tg-AD + mAb) (Fig. 1a), the pattern of tau truncation at the N-terminal domain along with its in vivo sensitivity to specific antibody-mediated engagement/clearance.